A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
Kathryn E. Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E. Kyriakopoulos, Randy F. Sweis, Marc C. Chamberlain, Brian I. Rini
Topics & Concepts
PembrolizumabMedicineTolerabilityRenal cell carcinomaInternal medicineAdverse effectProgressive diseaseOncologyPharmacodynamicsResponse Evaluation Criteria in Solid TumorsPharmacokineticsNivolumabGastroenterologyPharmacologyImmunotherapyCancerDiseaseImmune cells in cancerCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis